The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
Articles by Natasha Yetman
Gout & Its Comorbidities
At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.
Dare to Say No
Experts Whitney Marvin, MD, and Jinoos Yazdany, MD, discuss how to find synergy between work & career to better manage work/life conflicts and avoid burnout as rheumatologists.
The Pandemic’s End: What Do the Ending National Emergency Proclamations Mean for Healthcare?
As COVID-19 case counts fade from the headlines and people return to their pre-pandemic routines, rheumatologists and rheumatology professionals may be wondering what “the end” of COVID-19 is going to look like for them. Much of that answer lies in the status of the federal emergencies that have been declared in response to COVID-19. These…
Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis
In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…
How the U.S. Will Set Up New Medicare Drug Price Talks
WASHINGTON—The U.S. government will soon begin hiring experts and collecting the data needed to launch direct negotiations over prescription drug prices for older and disabled people, a top Biden administration official told Reuters. President Joe Biden last week signed into law the Inflation Reduction Act, introducing new policies to tackle climate change, taxes and the…
Letter to the Editor: Weathering Storms
We read the article, “Rheumatologists Share Lessons Learned in the Wake of Hurricane Ida” (July 2022, The Rheumatologist), with great interest. This poignant account of the impacted patients and rheumatologists provides invaluable planning tips regarding medication loss, access to pharmacies and medical records, and strategies to avoid practice losses. The critical lessons presented in this…
Some Cannabis Products May Ease Chronic Pain, But Side Effects Are a Concern
NEW YORK (Reuters Health)—Oral synthetic cannabis products that have a high tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio, as well as extracted cannabis products with comparable THC-to-CBD ratios, may provide moderate, short-term improvements in chronic pain, a large systematic review of relevant research suggests.1 However, these products are also associated with higher risks for side effects,…
Gene Profiling May Predict Treatment Response in Refractory Rheumatoid Arthritis
NEW YORK (Reuters Health)—In patients with rheumatoid arthritis (RA) refractory to treatment with rituximab or tocilizumab, genetic profiling of synovial biopsies predicted the lack of therapeutic response better than a model using only tissue pathology or clinical factors, researchers say.1 “We believe this study is a paradigm shift in precision medicine in RA,” Dr. Costantino…
Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients
In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is…
- 1
- 2
- 3
- …
- 97
- Next Page »